SUSMED

Susmedo introduces its systems for streamlining clinical trials, including Susmedo System and Susmedo SDS.

Susmed manages public research funding allocations.

Susmed and Nippon KemiPharma are discussing clinical trial efficiency using Susmed’s blockchain technology.

Tohoku University, the Japanese Society of Renal Rehabilitation, and Susmed are jointly developing a treatment app for chronic kidney disease patients.

Susmed’s AI analysis system contributed to research with Aomonomori Cancer Hospital, published in the Medical Informatics journal.

Susmed discloses research funding information under the Clinical Research Act.

Susmed posts financial statements for periods after the 7th fiscal year on the Financial Services Agency’s EDINET platform.

Susmed provides financial statement materials.

Susmed offers investor relations information.

Susmed shares recruitment details and job descriptions.

Susmed outlines its information security policy.

Susmed develops treatment smartphone apps and systems to streamline clinical trials and research.

Susmed introduces corporate information, including messages from leadership, partner research institutions, and access details.

Susmed outlines its approach to corporate governance, emphasizing efficiency, transparency, and compliance.

The page instructs users to fill out a form and submit it for inquiries, with personal data handled according to the company’s privacy policy.

Susmedo develops systems to improve efficiency in clinical trials, medical app development, and pharmaceutical research.

Susmedo provides its privacy policy.

Susmed’s website includes forward-looking statements based on current information, subject to risks and uncertainties.

Susmed discloses corporate information promptly under financial laws and Tokyo Stock Exchange rules.

Susmed aims for sustainable medicine through stakeholder feedback and employee dignity initiatives, including anti-harassment policies.